In mammals, the suprachiasmatic nucleus (SCN) is responsible for the generation of most circadian rhythms and for their entrainment to environmental cues. Carbachol, an agonist of acetylcholine (ACh), has been shown to shift the phase of circadian rhythms in rodents when injected intracerebroventricularly.
In mammals, the suprachiasmatic nucleus (SCN) is responsible for the generation of most circadian rhythms and for their entrainment to environmental cues. Carbachol, an agonist of acetylcholine (ACh), has been shown to shift the phase of circadian rhythms in rodents when injected intracerebroventricularly.
However, the site and receptor type mediating this action have been unknown. In the present experiments, we used the hypothalamic brain-slice technique to study the regulation of the SCN circadian rhythm of neuronal firing rate by cholinergic agonists and to identify the receptor subtypes involved. We found that the phase of the oscillation in SCN neuronal activity was reset by a 5 min treatment with a carbachol microdrop (1 ~1, 100 PM), but only when applied during the subjective night, with the largest phase shift (+6 hr) elicited during the middle of the subjective night. This effect also was produced by ACh and two muscarinic receptor (mAChR) agonists, muscarine and McN-A-343 (Ml-selective), but not by nicotine. Furthermore, the effect of carbachol was blocked by the mAChR antagonist atropine (0.1 PM), not by two nicotinic antagonists, dihydro-6-erythroidine (10 PM) and d-tubocurarine (10 PM). The Ml -selective mAChR antagonist pirenzepine completely blocked the carbachol effect at 1 PM, whereas an M3-selective antagonist, 4,2-(4,4'-diacetoxydiphenylmethyl)pyridine, partially blocked the effect at the same concentration. These results demonstrate that carbachol acts directly on the SCN to reset the phase of its firing rhythm during the subjective night via an Ml -like mAChR.
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The suprachiasmatic nucleus (SCN) of the hypothalamus has been identified as a primary pacemaker for circadian rhythms in mammals. Circadian rhythms are synchronized to environmental cues such as the solar light-dark cycle by afferent signals that have complex interactions with the SCN pacemaker. Brief light pulses administered to animals maintained in continuous darkness are capable of shifting the phase of their behavioral and physiological rhythms in a direction that depends on the time of administration of the pulse (De Coursey, 1964) . Pharmacological studies have revealed a number of chemical agents that phase-shift circadian rhythms in rodents (for review,. see Rusak and Bina, 1990) . Carbachol, an agonist of acetylcholine (ACh), has been reported to induce phase shifts in the circadian rhythm of pineal N-acetyltransferase (NAT) activity in rats and locomotor activity in mice and hamsters. Phase shifts were similar to those induced in response to brief light pulses, namely, delays in early subjective night and advances in late subjective night (Zatz and Brownstein, 1979; Zatz and Herkenham, 1981; Earnest and Turek, 1983,1985; Wee et al., 1992) . However, Meijer et al. (1988) reported that carbachol induced only phase advances. Because almost all of these in viva studies used intracerebroventricular injection, the site of action could not be determined. Recei ved June 27, 1995; revised Oct. 13, 1995; accepted Oct. 17, 1995 et al., 1975; van den Pol and Tsujimoto, 1985; Ichikawa and Hirata, 1986; Rao et al., 1987; Tago et al., 1987) . Using monoclonal antibodies against the muscarinic and nicotinic ACh receptors (mAChR, nAChR), both antigens were identified within the rat SCN (van der Zee et al., 1991) . More recently, the sites of cholinergic neurons that project to the SCN area have been identified (Bina et al., 1993) and include the basal nuclear complex of the forebrain and the laterodorsal tegmental, pedunculopontine tegmental, and parabigeminal nuclei of the brainstem. Although the functional significance of these pathways remains to be determined, it has been speculated that they are part of a feedback loop between the regulation of sleep/arousal and the circadian timing system (Bina et al., 1993) .
The receptor mechanisms underlying the effect of carbachol on circadian rhythms have been uncertain (for review, see Rusak and Bina, 1990) . Although nicotinic sites appeared to mediate the light-like influence of carbachol on pineal NAT activity, a role for muscarinic receptors was not ruled out (Zatz and Brownstein, 1981) . In a recent study using the brain-slice preparation, bathapplied nicotine, but not carbachol, was reported to phaseadvance the SCN neuronal activity rhythm (Trachsel et al., 1995) . A majority of SCN neurons were excited by iontophoresis of ACh (Nishino and Koizumi, 1977) or by systemic injection of cholinergic agonists (Miller et al., 1987) in rats. However, the effects of ACh on the activity of the SCN neurons recorded in vitro were predominantly inhibitory (Shibata et al., 1983; Kow and Pfaff, 1984) and could be blocked by atropine (Kow and Pfaff, 1984) indicating the involvement of mAChRs. Spontaneous neuronal firing of the SCN in the hypothalamic brain slice is patterned, appearing as a circadian oscillation (Green and Gillette, 1982) that is stable for at least three cycles (Prosser and Gillette, 1989) . In the present study, we evaluated the temporal sensitivity of this rhythm of neuronal firing in the SCN to direct cholinergic stimulation in vitro.
We sought to answer the following questions. (1) Can cholinergic agonists act directly on the SCN to alter the phase of the neuronal activity rhythm in the isolated rat SCN? (2) If so, which receptors are involved in the cholinergic regulation?
Preliminary findings of this study have been reported in abstract form (Liu and Gillette, 1994 
RESULTS
Carbachol applied to the SCN resets the neuronal firing rhythm during subjective night The sensitivity of the isolated pacemaker to cholinergic resetting of its phase was examined by applying microdrops (100 PM, 1 ~1) of the cholinergic agonist carbachol directly to each of the paired SCN in a hypothalamic brain slice for 5 min. The rhythm of firing rate was examined the next day. When a microdrop containing 100 pM carbachol in medium was applied in the middle of the subjective day at CT 6 on day 1, the subsequent peak in electrical activity occurred at CT 6.3 -C 0.1 (n = 3) on day 2. An example of the rhythm of one SCN treated at CT 6 appears in Figure 1A . This time-of-peak is not significantly different from media-treated controls (CT 6.8 -+ 0.1,~ > 0.05; II = 5). In contrast, when SCN were exposed to an identical treatment during mid-subjective night at CT 18 on day 1, the pattern of firing rate in the next cycle (day 2) was altered. Peak activity no longer occurred near CT 7, the normal peak time, or the time in media-treated control; rather, the peak occurred early (Fig. lB) , at CT 0.7 i-0.2 (n = 3) the next day. Compared with the time-of-peak on day 2 of media-treated control experiments (CT 6.8 5 0.1; n = 5) this represents a mean advance of the phase (@I) of 6.1 hr (p < 0.0001). To determine whether these phase advances were stable, we monitored the electrical activity rhythm for a second cycle after treatment (day 3 in vitro). As shown in Figure lC , the time of peak firing rate was again at CT 1.0 in the second cycle after treatment of carbachol at CT 18.
It is possible that carbachol diffused away from the site of . . apphcatton and the effect measured was attributable to its action on a structure in the hypothalamic slice outside the SCN. Therefore, we used a reduced slice preparation that contained only SCN, the underlying optic chiasm, and a small rim of hypothalamic tissue. The time of peak activity recorded from reduced slices was unchanged from that of the normal slice preparation (Gillette and Reppert, 1987) . When applied as a microdrop to these SCN, carbachol still shifted the rhythm in the same way (peak = CT 0.8, &I = 6 hr; II = 2). Thus, we conclude that carbachol stably phase-shifts the neuronal activity rhythm of the SCN via direct action on the SCN. To characterize the differential temporal sensitivity of the pacemaker to carbachol more fully, we examined the effects of carbachol microdrops (100 PM) applied for 5 min at various points in the circadian cycle. Because the advanced peak in firing activity appeared 6-7 hr after carbachol treatment at CT 18, and activity peaked again 24 hr later, the phase changes induced by carbachol appeared to be completed within 6-7 hr after the treatment of carbachol. Therefore, the phase changes in this series of experiments were determined during the cycle after treatment. The resulting relationship between the circadian phase of treatment and the response of the pacemaker, a phase-response curve, is shown in Figure 2 . When applied at points throughout the subjective day, carbachol induced little or no change (+0.9 -+ 0.2 hr, between CT 0 and CT 12; II = 7). Circadian Time Figure 2 . Relationship between the circadian time of carbachol treatment and its effect on the phase of the firing activity rhythm. The phase shifts induced by a 5 min exposure to 100 pM carbachol in 1 ~1 droplets at various circadian times were measured, and the average magnitudes of phase shifts % SEM (n = 3-6) were plotted. This figure is based on measurements across the 24 hr circadian cycle with a total of 21 experiments. Experiments were performed at 12 circadian times, which were grouped in 2 hr bins, and the means were plotted at the midpoint of the bin. The number of experiments in each bin is noted. For each experiment, the time-of-peak activity rhythm is based on the rhythm derived from measurements of 41-66 cells. Treatment during subjective night (horizontal bar) caused a significant phase advance in the peak of the circadian rhythm of electrical activity. The largest phase advance occurred at CT 17-19 (+6.1 -t 0.3 hr; n = 6), whereas treatment during subjective daytime (CT O-12) had little effect on the rhythm.
However, the SCN circadian rhythms were reset significantly by carbachol throughout subjective night: the largest phase changes (+6.1 ? 0.3 hr; n = 6) occurred when carbachol was applied between CT 17 and CT 19.
The effect of carbachol is dose-dependent and mimicked by ACh and by muscarinic agonists, but not by nicotine Dose-response relationships were determined at CT 18, the time of maximal phase shift to carbachol. Examination of the doseresponse relationship for carbachol with the 5 min microdrop treatment shows that the half-maximal response occurred near 1 PM, whereas the maximal resporise (+6.3 hr) occurred at 10 PM. The neurotransmitter ACh induced a similar phase advance (+5.3 hr) at 0.1 PM. Effects of two muscarinic agonists, muscarine and the Ml-selective
McN-A-343, also were tested at a range of concentrations.
They both induced a phase advance with the largest phase advances (+6.5 hr for at 1 FM and +6.3 hr for muscarine at 100 PM) within the amplitude range of those induced by carbachol (Figs. 3, 4) . The nAChR agonist nicotine had no effect at concentrations of 1 and 10 PM (n = 3). At 100 PM nicotine induced very small phase advances (+1.2 -t 0.3 hr; n = 3), which were statistically significant (0.001 < p < 0.05; Figs. 3,  4) . The relative potency of these agonists in shifting the SCN rhythm is as follows: ACh > McN-A-343 > carbachol = musca- rine >> nicotine (Fig. 4) . These experiments suggest that mAChRs mediate cholinergic regulation of the SCN rhythm at night.
The effect of carbachol is not affected by nicotinic antagonists To confirm that an nAChR is not involved in the carbacholinduced phase shift, the effect of a competitive nicotinic antagonist, dihydro-/3-erythroidine (DHPE), was examined. DHPE (10 PM)
did not affect the time-of-peak of the SCN activity rhythm when bath-applied for 30 min surrounding CT 18 (peak of CT 6.8 -C 0.1 hr, IZ = 3; Fig. 54) ; nor did the DHPE treatment attenuate the 6 hr phase advance induced by the 5 min carbachol (100 PM) microdrop at the middle of the DHpE pulse, at CT 18 (+6.0 2 0.1 hr, n = 3; Fig. 5B ). DHPE has been shown to block nicotinic depolarizations of neurons in the brain slices at concentrations of 10 PM to 10 PM (Wang et al., 1991; Stevens et al., 1993) . Because nAChRs in central nervous system neurons are diverse, the effectiveness of a second nicotinic antagonist, d-tubocurarine, in blocking the effect of carbachol was tested. d-Tubocurarine may act at a different subtype of neuronal nAChR. Application of d-tubocurarine (10 PM) for 30 min did not shift the SCN-activity rhythm (data not shown) or block the carbachol-induced phase advance at CT 18 (n = 3; Fig. 5C ). These results demonstrate that The specific nicotinic agonist nicotine had no effect at concentrations of 1 and 10 pM, but induced a small phase advance (+1.2 2 0.3 hr; n = 3) at the highest treatment level (100 WM).
the activation of nAChR is not required in the phase-shifting effect induced by carbachol. effect of carbachol (100 PM) at CT 18 at a concentration of 1 PM (+0.67 -C 0.08 hr, y1 = 3; Figs. 6, 7) and less effectively at 0.1 PM (+3.9 + 0.1 hr; II = 3). 4-DAMP, which is M3-selective, partially blocked the effect of carbachol at a concentration of 1 PM (+4.1 ? 0.1 hr, II = 3; Fig. 7) . The relative potency of the muscarinic antagonists in blocking the effect of carbachol is as follows: atropine > pirenzepine > 4-DAMP. Figure 3 . nally restricted pattern and via an mAChR mechanism. The specific findings of our experiments were as follows. (1) The SCN circadian rhythm was phase-advanced up to 6 hr by direct application of the cholinergic agonist carbachol to the SCN in the brain slice, and sensitivity to carbachol was circadian phase-dependent, occurring only during the subjective night. (2) This change in sensitivity is driven by endogenous clock mechanisms because it occurred in the isolated SCN in V&U>. (3) The phase-shifting effect of carbachol was reproduced by ACh and two muscarinic agonists, muscarine and M&J-A-343 (Ml-selective), but not by nicotine.. (4) The nAChR antagonist DHpE (10 PM) did not affect the carbachol-induced phase advance. (5) Both the muscarinic antagonist atropine (0.1 PM) and the Ml-selective antagonist pirenzepinc (1 FM) blocked the carbachol phase-shifting effect, whereas the M3-selective antagonist 4-DAMP (1 ~L;M) partially blocked the effect.
DISCUSSION
Site of action The site at which carbachol affects circadian rhythms has resisted identification in whole-animal studies. The observation that intracerebroventricular injection of this cholincrgic agonist causes phase shifts has suggested that it acts within the SCN or at A, A 30 min bath application of atropine (KIYU; 1 pM) alone surrounding CT 1X had no effect on the activity rhythm. B, AIropine (0.1 p.M) blocked the effect of a 5 min carbach (CARB) microdrop (compare Fig. 1 ). C, The selective Ml antagonist pirenzepine (PZU; 1 FM) also blocked the effect of carbachol at CT 18; pirenzepine alone bad no effect on phase (data not shown). Symbols are as in Figure 5. neurons that project to the SCN. In the present study, we demonstrated that carbachol can induce the same phase shift in the reduced slice preparation (limited to the SCN region) as it does in the hypothalamic slice. Therefore, carbachol must act directly on the SCN or in its immediate vicinity to induce the phase shift of the SCN neuronal activity rhythm, AIthough we cannot exclude the possibility that carbachol acted on optic nerve terminals that remain in this reduced preparation, the most likely site of action is on SCN neurons, which express both muscarinic and nicotinic receptors (van der Zee et al., 1991) .
Our study of the response of the SCN ipl vitro does not rule out the possibility that, in addition to acting directly on SCN neurons, carbachol injected jntracerebroventricularly in viva acts indirectly at different brain sites on neurons that project to the SCN to exert its effect on the behavioral circadian rhythms. Although earty studies showed a light-like effect of intracerebroventricularly injected carbachol on wheel-running activity (Zatz and Herkenham, 1981) tergic system at sites not preserved well in the SCN brain slice (see below); this may modify its direct effect on the SCN pacemaker.
Receptor subclasses and subtypes
Carbachol is a nonselective cholinergic agonist that activates mAChR and nAChR subclasses. Previous studies of the effect of carbachol on the circadian rhythms in viva were not conclusive as to receptor mechanism. The neurophysiological effects of cholinergic agents on SCN cells are also controversial. In the present study, we found that large-amplitude phase shifts induced by carbachol at CT 18 were produced by other cholinergics with the potency rank order as follows: ACh > McN-A-343 > carbachol F= muscarine. These effects were not produced by nicotine (l-100 PM).
In addition, the muscarinic antagonists atropine and pirenzepine blocked the effect of 100 PM carbachol at 0.1 and 1 PM concentrations, whereas two nicotinic antagonists, DHpE and d-tubocurarine, did not show any blocking effect at a concentration of 10 pM. These results demonstrate that nAChR activation is unlikely to contribute significantly to phase-shifting the circadian clock at CT 18; rather, mAChR-mediated mechanisms can access the clock in its nocturnal state.
Our results differ from those of a recent study (Trachsel et al., 1995) which reported that the SCN rhythm was advanced by 2 hr on average, independent of the CT, by nicotine. That paradigm examined the response to nicotine (10 PM for 1 hr in the bath) applied across the circadian cycle. Our results do not dispute the report that nicotine can cause small phase advances. We also observed that nicotine (100 FM in a microdrop) caused a small phase advance (1.2 hr; see Fig. 4 ). However, they reported that carbachol was without effect. Although the discrepancy between the studies could be attributable to the differences in the methods of treatment and rat strains used, it should be noted that Trachsel et al. (1995) did not test the effect of carbachol between CT 1.5 and CT 21, which we demonstrate in this study to be the most sensitive period for carbachol to induce the phase shift.
Molecular
cloning techniques have identified five genes (ml, m2, m3, m4, and m5) that encode distinct mAChRs. The ml, m2, m3, and m4 subtypes correspond to pharmacologically classified receptors Ml, M2, M3, and M4, respectively (Watson and Abbot, 1992) . Which of these might be expressed in the SCN is unknown.
Our results suggest that carbachol activates an Ml mAChR in the SCN to phase-shift circadian rhythms. Although the mAChR subtypes have different sensitivity to the agonists and antagonists, they cannot be differentiated exclusively with these drugs. is functionally potent in stimulating the Ml receptor but has less activity at M2 and M3; it shows little selectivity for these subtypes in the binding assay (Birdsall et al., 1983; Freedman et al., 1988; Lambrecht et al., 1993) . In the present study, mimicked the effect of carbachol at CT 18 at low concentrations and was more potent than carbachol and muscarine (see Fig. 4) . Although it is possible that the phase-response curves for these cholinergic agonists are different so that their relative potencies could be different at circadian times other than CT 18, the fact that the maximum phase shifts induced by these agonists at CT 18 are comparable does not support this possibility. The Ml-selective antagonist pirenzepine (1 PM) blocked the phase-shifting effect of carbachol, whereas an M3 antagonist, 4-DAMP, partially blocked the effect at the same concentration. Although both pirenzepine and 4-DAMP have high affinities for the Ml subtype, with 4-DAMP slightly higher, pirenzepine has >40-fold lower affinities than does 4-DAMP for M2, M3, and M4 subtypes (Doods et al., 1987; Waelbroeck et al., 1990) . Our results regarding potency rank order of the agonists and antagonists are mostly consistent with the interpretation that the phase-shifting effect of cholinergic agonists on the SCN activity rhythm is mediated via an Ml mAChR. However, it should be noted that these pharmacological data do not exclude the possibility of the involvement of an m5-like subtype of mAChR or a mixture of mAChR subtypes in regulating the SCN rhythm. Therefore, further studies are needed to identify with certainty the subtype(s) coupled with the ACh response when more selective agonists and antagonists become available.
Phase-dependent sensitivity and relationship to light pulses in vivo Although the ACh agonist carbachol is the only agent that has been reported to "mimic" the phase-shifting effects of light when injected in vivo (Zatz and Brownstein, 1979; Zatz and Herkenham, 1981; Earnest and Turek, 1983, 1985; Wee et al., 1992) , the other evidence for the involvement of ACh in light-induced phase shifts is weak. This has been referred to as "the carbachol paradox" by Colwell et al. (1993) . Our results reveal that the SCN clock is sensitive to carbachol only during the subjective night of the circadian cycle. This timing of SCN sensitivity to carbachol is mostly consistent with results from in vivo experiments. However, the patterns of response in the two conditions differ. The response to intracerebroventricular injection of carbachol in vivo can be biphasic, with phase delays in wheel-running rhythms during early night and phase advances during late night. We did not observe a phase delay in vitro, which suggests that a phase delay induced by carbachol in vivo is not attributable to the direct effect of carbachol on the SCN. It has been shown that cholinergic fibers in the SCN region originate from cholinergic neurons in the cholinergic basal nuclear complex and in the mesopontine tegmentum. It has been speculated that these pathways provide feedback regulation of circadian timing relative to the state of sleep and wakefulness (Bina et al., 1993) . Therefore, direct stimulation of these areas in viva would be predicted to cause phase shifts in behavioral circadian rhythms with patterns of sensitivity like the SCN sensitivity to carbachol.
Although cholincrgic stimulation of the SCN in vitro dots not generate the biphasic phase shifts induced by light, glutamate, the putative neurotransmitter in the RHT, does reproduce this effect. 
